勃林格殷格翰-话题@MedSci

#勃林格殷格翰#

67篇内容 | 1229人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2106352, encodeId=745b210635244, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a><a href='/topic/show?id=456a966ee9' target=_blank style='color:#2F92EE;'>#IL-36R#</a>单抗<a href='/topic/show?id=c564105082ba' target=_blank style='color:#2F92EE;'>#佩索利单抗#</a><a href='/topic/show?id=4b3d104922f2' target=_blank style='color:#2F92EE;'>#spesolimab#</a>治疗<a href='/topic/show?id=ec6f6488874' target=_blank style='color:#2F92EE;'>#泛发性脓疱型银屑病#</a>, objectTitle=勃林格殷格翰IL-36R单抗spesolimab治疗银屑病在中国获批, objectType=article, longId=752204, objectId=ab9be52204ef, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20221123/b0bdc609c9394292ac843dcac3e87f70.jpg, objectUrl=/article/show_article.do?id=ab9be52204ef, replyNumber=0, likeNumber=58, createdTime=2022-12-16, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=ab9be52204ef, moduleTitle=勃林格殷格翰IL-36R单抗spesolimab治疗银屑病在中国获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab9be52204ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447271, encodeId=4970144e27168, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, objectTitle=勃林格殷格翰收购生物制药公司 Abexxa Biologics, objectType=article, longId=217712, objectId=c31021e712b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c31021e712b2, replyNumber=0, likeNumber=36, createdTime=2021-09-28, rootId=0, userName=ymljack, userId=7ae75331052, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c31021e712b2, moduleTitle=勃林格殷格翰收购生物制药公司 Abexxa Biologics, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c31021e712b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447270, encodeId=8793144e27048, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, objectTitle=勃林格殷格翰同类首创在研免疫新药Spesolimab获得CDE突破性治疗药物认定, objectType=article, longId=213247, objectId=3f8321324e7a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f8321324e7a, replyNumber=0, likeNumber=30, createdTime=2021-06-27, rootId=0, userName=ymljack, userId=7ae75331052, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f8321324e7a, moduleTitle=勃林格殷格翰同类首创在研免疫新药Spesolimab获得CDE突破性治疗药物认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f8321324e7a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447269, encodeId=f6ea144e26996, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, objectTitle=勃林格殷格翰携手克睿基因，共同开发下一代具有突破性的基因疗法, objectType=article, longId=205936, objectId=c473205936f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c473205936f0, replyNumber=0, likeNumber=34, createdTime=2021-01-22, rootId=0, userName=ymljack, userId=7ae75331052, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c473205936f0, moduleTitle=勃林格殷格翰携手克睿基因，共同开发下一代具有突破性的基因疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c473205936f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447268, encodeId=879a144e268ed, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, objectTitle=FDA扩展了勃林格殷格翰的尼达尼布的适应症，用于治疗具有进展表型的慢性纤维化间质性肺病, objectType=article, longId=189668, objectId=1f7f18966870, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f7f18966870, replyNumber=0, likeNumber=26, createdTime=2020-03-12, rootId=0, userName=ymljack, userId=7ae75331052, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f7f18966870, moduleTitle=FDA扩展了勃林格殷格翰的尼达尼布的适应症，用于治疗具有进展表型的慢性纤维化间质性肺病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f7f18966870)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447267, encodeId=f130144e2678b, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, objectTitle=勃林格殷格翰广撒“英雄帖” 生物医药“创新大赛”正式启动, objectType=article, longId=182733, objectId=c156182e33f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c156182e33f6, replyNumber=0, likeNumber=42, createdTime=2019-11-10, rootId=0, userName=ymljack, userId=7ae75331052, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c156182e33f6, moduleTitle=勃林格殷格翰广撒“英雄帖” 生物医药“创新大赛”正式启动, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c156182e33f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447266, encodeId=10f6144e2667a, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, objectTitle=cell:北京大学张泽民课题组与勃林格殷格翰联合发表关于单细胞测序刻画肝癌免疫微环境动态特征的研究, objectType=article, longId=182230, objectId=ec8518223099, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec8518223099, replyNumber=0, likeNumber=34, createdTime=2019-11-03, rootId=0, userName=ymljack, userId=7ae75331052, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec8518223099, moduleTitle=cell:北京大学张泽民课题组与勃林格殷格翰联合发表关于单细胞测序刻画肝癌免疫微环境动态特征的研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec8518223099)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447265, encodeId=476a144e26550, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, objectTitle=**名患者参加勃林格殷格翰的钠通道抑制剂治疗囊性纤维化的II期临床试验, objectType=article, longId=181606, objectId=fdfc181606fb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdfc181606fb, replyNumber=0, likeNumber=29, createdTime=2019-10-21, rootId=0, userName=ymljack, userId=7ae75331052, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdfc181606fb, moduleTitle=**名患者参加勃林格殷格翰的钠通道抑制剂治疗囊性纤维化的II期临床试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fdfc181606fb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447264, encodeId=e15b144e26465, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, objectTitle=勃林格殷格翰的多途径激酶抑制剂Ofev治疗慢性纤维化间质性肺病，获得FDA的突破性治疗指定, objectType=article, longId=181137, objectId=82d718113e9c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=82d718113e9c, replyNumber=0, likeNumber=40, createdTime=2019-10-16, rootId=0, userName=ymljack, userId=7ae75331052, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=82d718113e9c, moduleTitle=勃林格殷格翰的多途径激酶抑制剂Ofev治疗慢性纤维化间质性肺病，获得FDA的突破性治疗指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=82d718113e9c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447263, encodeId=09d1144e263af, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, objectTitle=勃林格殷格翰发布“卒中全病程解决方案” ，将亮相第二届进博会, objectType=article, longId=180782, objectId=dcea180e82bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dcea180e82bd, replyNumber=0, likeNumber=45, createdTime=2019-10-10, rootId=0, userName=ymljack, userId=7ae75331052, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dcea180e82bd, moduleTitle=勃林格殷格翰发布“卒中全病程解决方案” ，将亮相第二届进博会, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dcea180e82bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447262, encodeId=7ff7144e26203, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, objectTitle=勃林格殷格翰与MD安德森建立了"虚拟研究"联盟, objectType=article, longId=177616, objectId=c4fe1e761607, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4fe1e761607, replyNumber=0, likeNumber=38, createdTime=2019-08-16, rootId=0, userName=ymljack, userId=7ae75331052, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4fe1e761607, moduleTitle=勃林格殷格翰与MD安德森建立了"虚拟研究"联盟, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4fe1e761607)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447261, encodeId=71da144e26112, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, objectTitle=慢性心力衰竭：FDA授予礼来和勃林格殷格翰的SGLT2抑制剂Jardiance快速通道资格, objectType=article, longId=174322, objectId=0d4b1e4322ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d4b1e4322ee, replyNumber=0, likeNumber=31, createdTime=2019-06-29, rootId=0, userName=ymljack, userId=7ae75331052, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d4b1e4322ee, moduleTitle=慢性心力衰竭：FDA授予礼来和勃林格殷格翰的SGLT2抑制剂Jardiance快速通道资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d4b1e4322ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447260, encodeId=2860144e260c1, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, objectTitle=勃林格殷格翰官方电商平台“福来恩宠物用品旗舰店”登陆天猫, objectType=article, longId=160670, objectId=17691606e0c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17691606e0c3, replyNumber=0, likeNumber=37, createdTime=2019-02-22, rootId=0, userName=ymljack, userId=7ae75331052, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17691606e0c3, moduleTitle=勃林格殷格翰官方电商平台“福来恩宠物用品旗舰店”登陆天猫, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17691606e0c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447259, encodeId=5c9a144e25986, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, objectTitle=勃林格殷格翰携手AMPATH提升肯尼亚医疗保健提供者的知识技能, objectType=article, longId=158848, objectId=f6361588480d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f6361588480d, replyNumber=0, likeNumber=36, createdTime=2019-01-26, rootId=0, userName=ymljack, userId=7ae75331052, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f6361588480d, moduleTitle=勃林格殷格翰携手AMPATH提升肯尼亚医疗保健提供者的知识技能, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f6361588480d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447258, encodeId=1d18144e258a0, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, objectTitle=勃林格殷格翰中国生物制药合同生产基地产能扩容, objectType=article, longId=158404, objectId=61e515840491, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61e515840491, replyNumber=0, likeNumber=35, createdTime=2019-01-20, rootId=0, userName=ymljack, userId=7ae75331052, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61e515840491, moduleTitle=勃林格殷格翰中国生物制药合同生产基地产能扩容, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61e515840491)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447257, encodeId=2b73144e25760, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, objectTitle=邓迪大学与勃林格殷格翰合作通过opnMe.com免费提供PROTAC化合物, objectType=article, longId=157794, objectId=0a5a15e79411, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0a5a15e79411, replyNumber=0, likeNumber=40, createdTime=2019-01-12, rootId=0, userName=ymljack, userId=7ae75331052, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0a5a15e79411, moduleTitle=邓迪大学与勃林格殷格翰合作通过opnMe.com免费提供PROTAC化合物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0a5a15e79411)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447256, encodeId=eb55144e2569f, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, objectTitle=勃林格殷格翰通过与Dicerna的研究合作取得第二个肝病靶点的期权, objectType=article, longId=157792, objectId=26c515e792bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26c515e792bf, replyNumber=0, likeNumber=40, createdTime=2019-01-12, rootId=0, userName=ymljack, userId=7ae75331052, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26c515e792bf, moduleTitle=勃林格殷格翰通过与Dicerna的研究合作取得第二个肝病靶点的期权, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=26c515e792bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447255, encodeId=df2e144e25515, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, objectTitle=Xynomic制药从勃林格殷格翰获得mTORC1 / 2抑制剂的全球**经营权, objectType=article, longId=156446, objectId=8726156446da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8726156446da, replyNumber=0, likeNumber=35, createdTime=2018-12-24, rootId=0, userName=ymljack, userId=7ae75331052, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8726156446da, moduleTitle=Xynomic制药从勃林格殷格翰获得mTORC1 / 2抑制剂的全球**经营权, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8726156446da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447254, encodeId=4d36144e254d6, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, objectTitle=勃林格殷格翰VAXXITEK(R)HVT+ IBD疫苗累计接种家禽逾千亿羽, objectType=article, longId=155889, objectId=e44415588980, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e44415588980, replyNumber=0, likeNumber=39, createdTime=2018-12-17, rootId=0, userName=ymljack, userId=7ae75331052, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e44415588980, moduleTitle=勃林格殷格翰VAXXITEK(R)HVT+ IBD疫苗累计接种家禽逾千亿羽, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e44415588980)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1447253, encodeId=cf72144e25375, content=<a href='/topic/show?id=16c6334194b' target=_blank style='color:#2F92EE;'>#勃林格殷格翰#</a>, objectTitle=勃林格殷格翰成为“关爱猫咪生命”官方合作伙伴, objectType=article, longId=153258, objectId=73ed15325896, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=73ed15325896, replyNumber=0, likeNumber=40, createdTime=2018-11-13, rootId=0, userName=ymljack, userId=7ae75331052, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=73ed15325896, moduleTitle=勃林格殷格翰成为“关爱猫咪生命”官方合作伙伴, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=73ed15325896)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

2020-05-29

循证小兵 (审核中...)

前往app查看评论内容

#勃林格殷格翰##IL-36R#单抗#佩索利单抗##spesolimab#治疗#泛发性脓疱型银屑病#

勃林格殷格翰IL-36R单抗spesolimab治疗银屑病在中国获批

2022-12-16发表于上海

ymljack (审核中...)

前往app查看评论内容

#勃林格殷格翰#

勃林格殷格翰收购生物制药公司 Abexxa Biologics

2021-09-28

ymljack (审核中...)

前往app查看评论内容

#勃林格殷格翰#

勃林格殷格翰同类首创在研免疫新药Spesolimab获得CDE突破性治疗药物认定

2021-06-27

ymljack (审核中...)

前往app查看评论内容

#勃林格殷格翰#

勃林格殷格翰携手克睿基因，共同开发下一代具有突破性的基因疗法

2021-01-22

ymljack (审核中...)

前往app查看评论内容

#勃林格殷格翰#

FDA扩展了勃林格殷格翰的尼达尼布的适应症，用于治疗具有进展表型的慢性纤维化间质性肺病

2020-03-12

ymljack (审核中...)

前往app查看评论内容

#勃林格殷格翰#

勃林格殷格翰广撒“英雄帖” 生物医药“创新大赛”正式启动

2019-11-10

ymljack (审核中...)

前往app查看评论内容

#勃林格殷格翰#

cell:北京大学张泽民课题组与勃林格殷格翰联合发表关于单细胞测序刻画肝癌免疫微环境动态特征的研究

2019-11-03

ymljack (审核中...)

前往app查看评论内容

#勃林格殷格翰#

**名患者参加勃林格殷格翰的钠通道抑制剂治疗囊性纤维化的II期临床试验

2019-10-21

ymljack (审核中...)

前往app查看评论内容

#勃林格殷格翰#

勃林格殷格翰的多途径激酶抑制剂Ofev治疗慢性纤维化间质性肺病，获得FDA的突破性治疗指定

2019-10-16

ymljack (审核中...)

前往app查看评论内容

#勃林格殷格翰#

勃林格殷格翰发布“卒中全病程解决方案” ，将亮相第二届进博会

2019-10-10

ymljack (审核中...)

前往app查看评论内容

#勃林格殷格翰#

勃林格殷格翰与MD安德森建立了"虚拟研究"联盟

2019-08-16

ymljack (审核中...)

前往app查看评论内容

#勃林格殷格翰#

慢性心力衰竭：FDA授予礼来和勃林格殷格翰的SGLT2抑制剂Jardiance快速通道资格

2019-06-29

ymljack (审核中...)

前往app查看评论内容

#勃林格殷格翰#

勃林格殷格翰官方电商平台“福来恩宠物用品旗舰店”登陆天猫

2019-02-22

ymljack (审核中...)

前往app查看评论内容

#勃林格殷格翰#

勃林格殷格翰携手AMPATH提升肯尼亚医疗保健提供者的知识技能

2019-01-26

ymljack (审核中...)

前往app查看评论内容

#勃林格殷格翰#

勃林格殷格翰中国生物制药合同生产基地产能扩容

2019-01-20

ymljack (审核中...)

前往app查看评论内容

#勃林格殷格翰#

邓迪大学与勃林格殷格翰合作通过opnMe.com免费提供PROTAC化合物

2019-01-12

ymljack (审核中...)

前往app查看评论内容

#勃林格殷格翰#

勃林格殷格翰通过与Dicerna的研究合作取得第二个肝病靶点的期权

2019-01-12

ymljack (审核中...)

前往app查看评论内容

#勃林格殷格翰#

Xynomic制药从勃林格殷格翰获得mTORC1 / 2抑制剂的全球**经营权

2018-12-24

ymljack (审核中...)

前往app查看评论内容

#勃林格殷格翰#

勃林格殷格翰VAXXITEK(R)HVT+ IBD疫苗累计接种家禽逾千亿羽

2018-12-17

ymljack (审核中...)

前往app查看评论内容

#勃林格殷格翰#

勃林格殷格翰成为“关爱猫咪生命”官方合作伙伴

2018-11-13

科室
- - 订阅+
  - 更多科室
工具
服务